Louvain-la-Neuve, July 01, 2014 – International Drug Development Institute (IDDI), a corporation based in Belgium with ofﬁces in Boston (MA), Houston (TX) and Cupertino (CA) announces the appointment of Dr. Everardo Saad as Senior Medical Expert as of July 2014. Everardo brings over 12 years of experience in Medical Oncology with a special interest in clinical trial designs for stratiﬁed oncology and biomarker-based endpoints for a more efﬁcient development of novel therapies for cancer patients.
IDDI replaced its mix of a paper-based trial master file (TMF) and e-rooms with Veeva Systems’ cloud-based Vault eTMF solution, part of Veeva’s Development Suite. As a CRO that collects, analyses, and reports all data from international phase I through IV clinical trials for sponsors throughout the US, Europe, and Asia, IDDI wanted a single, centralised system to streamline auditing and collaboration.
They are talking about CluePoints....
IDDI reports successful partnership with Ophthotech in a Phase IIb study showing superior efficacy of Ophthotech's Novel Anti-PDGF Agent FovistaTM combined with Lucentis® over Lucentis® Monotherapy in Wet AMD.
IDDI announces publication of 'A statistical approach to central monitoring of data quality in clinical trials published in Clinical Trials' on June 8th. Online version is available at http://ctj.sagepub.com/content/early/2012/06/08/1740774512447898
IDDI reports successful partnership with Oraya Therapeutics for positive INTREPID Study Outcomes With a Non-Invasive Radiation Therapy for Wet AMD
IDDI (International Drug Development Institute) Reports Partnership with Exonhit for the clinical validation of diagnostic tests. Louvain-la-Neuve, March 28, 2012 – IDDI (International Drug Development Institute), a corporation based in Belgium, announces its collaboration with Exonhit (Alternext: ALEHT), a French biotechnology company focused on personalized medicine and developing targeted therapeutic and diagnostic products in oncology and Alzheimer’s disease.
The IWR/IVR system ID-net™ developed by IDDI now provides an interface to MARVIN, XClinical's EDC System.
IDDI reports 18% increase of the group revenues and 29% increase of sales for year 2010 compared to year 2009. Damien Tremolet, CEO, comments: "Biopharma companies are eagerly needing advanced and innovative statistical designs (such as adaptive or Bayesian designs) that can be presented to regulatory agencies. IDDI is uniquely positioned to provide such high added value expertise combined with unrivalled biostatistical and eClinical services including randomization and Electronic Data Capture."